IMPACT SCORE JOURNAL RANKING CONFERENCE RANKING Conferences Journals Workshops Seminars SYMPOSIUMS MEETINGS BLOG LaTeX 5G Tutorial Free Tools

Search About Journals, Conferences, and Book Series

Drug Design, Development and Therapy

Impact, Factor and Metrics, Impact Score, Ranking, h-index, SJR, Rating, Publisher, ISSN, and More

Last Updated on June 27, 2025

Impact Score

2024-2025

5.23

h-Index

2024-2025

 108

Rank

2024-2025

 3601

SJR

2024-2025

 1.19

Note: The impact score or impact index shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.

Important Metrics and Factor

Title Drug Design, Development and Therapy
Abbreviation Drug Des. Dev. Ther.
Publication Type Journal
Subject Area, Categories, Scope Drug Discovery (Q1); Pharmaceutical Science (Q1); Pharmacology (Q1)
h-index 108
Overall Rank/Ranking 3601
SCImago Journal Rank (SJR) 1.19
Impact Score 5.23
Publisher Dove Medical Press Ltd
Country New Zealand
ISSN 11778881
Best Quartile Q1
Coverage History 2007-2025




About Drug Design, Development and Therapy


Drug Design, Development and Therapy is a journal covering the technologies/fields/categories related to Drug Discovery (Q1); Pharmaceutical Science (Q1); Pharmacology (Q1). It is published by Dove Medical Press Ltd. The overall rank of Drug Design, Development and Therapy is 3601. According to SCImago Journal Rank (SJR), this journal is ranked 1.19. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 108. The best quartile for this journal is Q1.

The ISSN of Drug Design, Development and Therapy journal is 11778881. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Drug Design, Development and Therapy is cited by a total of 5610 articles during the last 3 years (Preceding 2024).


Drug Design, Development and Therapy Impact IF 2024-2025


The Impact IF 2024 of Drug Design, Development and Therapy is 5.23, which is computed in 2025 as per its definition. Drug Design, Development and Therapy IF is increased by a factor of 0.34 and approximate percentage change is 6.95% when compared to preceding year 2023, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Table Setting

Drug Design, Development and Therapy Impact IF 2025 Prediction


Impact IF 2024 of Drug Design, Development and Therapy is 5.23. If the same upward trend persists, Impact IF may rise in 2025 as well.


Impact IF Trend


Year wise Impact IF of Drug Design, Development and Therapy. Based on Scopus data.


Year Impact IF
2025/2026 Coming Soon
2024 5.23
2023 4.89
2022 4.83
2021 4.22
2020 3.89
2019 3.36
2018 3.22
2017 3.05
2016 3.04
2015 3.44
2014 3.52

Drug Design, Development and Therapy h-index


  Table Setting

Drug Design, Development and Therapy has an h-index of 108. It means 108 articles of this journal have more than 108 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.




Drug Design, Development and Therapy ISSN


The ISSN of Drug Design, Development and Therapy is 11778881. ISSN stands for International Standard Serial Number.

An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.

Table Setting

Drug Design, Development and Therapy Rank and SCImago Journal Rank (SJR)


The overall rank of Drug Design, Development and Therapy is 3601. According to SCImago Journal Rank (SJR), this journal is ranked 1.19. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.

SJR of Drug Design, Development and Therapy by Year


Year SJR
2025/2026 Coming Soon
2024 1.19
2023 0.999
2022 0.887
2021 0.784
2020 0.964
2019 0.880
2018 0.986
2017 0.974
2016 0.993
2015 0.982
2014 1.034

Ranking of Drug Design, Development and Therapy by Year


Year Ranking
2025/2026 Coming Soon
2024 3601
2023 4457
2022 5093
2021 5890
2020 4609
2019 5214
2018 4453
2017 4522
2016 4470
2015 4548
2014 4140

Drug Design, Development and Therapy Publisher


Table Setting

Drug Design, Development and Therapy is published by Dove Medical Press Ltd. It's publishing house is located in New Zealand. Coverage history of this journal is as following: 2007-2025. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.


Call For Papers


Visit the official website of the journal/conference to check the further details about the call for papers.


Abbreviation


The IS0 4 standard abbreviation of Drug Design, Development and Therapy is Drug Des. Dev. Ther.. This abbreviation ('Drug Des. Dev. Ther.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.

ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.


How to publish in Drug Design, Development and Therapy


If your research field is/are related to Drug Discovery (Q1); Pharmaceutical Science (Q1); Pharmacology (Q1), then please visit the official website of this journal.


Acceptance Rate


The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.

  • The demand or interest of researchers/scientists in publishing in a specific Journal/Conference.
  • Peer review complexity and timeline.
  • The mix of unsolicited and invited submissions.
  • The time it takes from manuscript submission to final publication.
  • And Many More.

It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.

The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.



Frequently Asked Questions (FAQs)


What's the latest impact IF of the Drug Design, Development and Therapy?

Drug Design, Development and Therapy latest impact IF is 5.23. It's evaluated in the year 2024. The highest and the lowest impact IF or impact score of this journal are 5.23 (2024) and 3.04 (2016), respectively, in the last 11 years. Moreover, its average IS is 3.88 in the previous 11 years.


What's the SCImago Journal Rank (SJR) of the Drug Design, Development and Therapy?

The Drug Design, Development and Therapy has an SJR (SCImago Journal Rank) of 1.19, according to the latest data. It is computed in the year 2025. In the past 11 years, this journal has recorded a range of SJR, with the highest being 1.19 in 2024 and the lowest being 0.784 in 2021. Furthermore, the average SJR of the Drug Design, Development and Therapy over the previous 11-year period stands at 3.88.


What's the latest h-index of the Drug Design, Development and Therapy?

The latest h-index of the Drug Design, Development and Therapy is 108.


Who's the publisher of the Drug Design, Development and Therapy?

The Drug Design, Development and Therapy is published by the Dove Medical Press Ltd, with its country of publication being the New Zealand.


What's the current ranking of the Drug Design, Development and Therapy?

The Drug Design, Development and Therapy is currently ranked 3601 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 11 years, this journal has experienced varying rankings, reaching its highest position of 3601 in 2024 and its lowest position of 5890 in 2021.


What's the abbreviation or short name for the Drug Design, Development and Therapy?

The standard ISO4 abbreviation for the Drug Design, Development and Therapy is Drug Des. Dev. Ther..


Is the "Drug Design, Development and Therapy" classified as a Journal, Conference and Proceedings, Trade Journal or Book Series?

Drug Design, Development and Therapy is classified as a journal that the Dove Medical Press Ltd publishes.


What's the scope or major areas of the Drug Design, Development and Therapy?

The Drug Design, Development and Therapy encompasses the following areas:

  • Drug Discovery
  • Pharmaceutical Science
  • Pharmacology

For a more comprehensive understanding of its scope, check the official website of this journal.


What's the ISSN of the Drug Design, Development and Therapy?

The Drug Design, Development and Therapy is assigned the following International Standard Serial Numbers (ISSN): 11778881.


What's the best quartile of the Drug Design, Development and Therapy?

The best quartile for the Drug Design, Development and Therapy is Q1 (2024).


What's the coverage history of the Drug Design, Development and Therapy?

The Drug Design, Development and Therapy coverage history can be summarized as follows: 2007-2025.


Credits and Sources


  • Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
  • Journal Impact Factor, https://clarivate.com/



Impact Score, h-Index, and Other Important Details of These Journals, Conferences, and Books


Journal/Conference/Workshop/Book Title Type Ranking Publisher h-index Impact Score
Dermatologia Kliniczna journal 25442 Cornetis 7 0.00
Proceedings of the ASME Turbo Expo conference and proceedings 17577 54 0.00
Clinical Medicine and Research journal 14921 Marshfield Clinic 64 1.25
Journal of Competition Law and Economics journal 11978 Oxford University Press 34 0.94
Modern Language Journal journal 1033 Wiley-Blackwell 123 3.95
Palaeontographica Abteilung B: Palaeophytologie book series 10600 Schweizerbart Science Publishers 18 4.25
Educational Measurement: Issues and Practice journal 6760 Wiley-Blackwell Publishing Ltd 68 1.54
Biological Procedures Online journal 5232 BioMed Central Ltd 51 4.00
Acta Periodica Technologica journal 22883 University of Novi Sad, Faculty of Technology 22 0.71
Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria journal 25905 National Association of Resident Doctors of Nigeria 25 0.00

Check complete list




Year wise Impact Score (IS) of Drug Design, Development and Therapy

Impact Score Table

Year Impact Score (IS)
2025/2026 Coming Soon
2024 5.23
2023 4.89
2022 4.83
2021 4.22
2020 3.89
2019 3.36
2018 3.22
2017 3.05
2016 3.04
2015 3.44
2014 3.52



Top Journals/Conferences in Drug Discovery

Nature Reviews Drug Discovery
Nature Research | United Kingdom

Protein and Cell
Oxford University Press | United Kingdom

Molecular Therapy
Cell Press | United States

Medicinal Research Reviews
John Wiley & Sons Inc. | United States

Cell Chemical Biology
Elsevier Ltd | United Kingdom

MedComm
John Wiley and Sons Inc | United States

Natural Product Reports
Royal Society of Chemistry | United Kingdom

Emerging Microbes and Infections
Taylor and Francis Ltd. | United Kingdom

Molecular Therapy - Nucleic Acids
Cell Press | United States

Archives of Pharmacal Research
Pharmaceutical Society of Korea | South Korea

See All

Top Journals/Conferences in Pharmaceutical Science

Advanced Drug Delivery Reviews
Elsevier B.V. | Netherlands

Nano Today
Elsevier B.V. | Netherlands

Journal of Controlled Release
Elsevier B.V. | Netherlands

Advanced healthcare materials
John Wiley and Sons Inc | United States

Journal of Nanobiotechnology
BioMed Central Ltd | United Kingdom

Asian Journal of Pharmaceutical Sciences
Shenyang Pharmaceutical University | China

Apoptosis : an international journal on programmed cell death
Springer | United States

Phytomedicine
Elsevier GmbH | Germany

Bioengineering and Translational Medicine
John Wiley and Sons Inc | United States

Journal of Pharmaceutical Analysis
Xi'an Jiaotong University | China

See All

Top Journals/Conferences in Pharmacology

Nature Reviews Drug Discovery
Nature Research | United Kingdom

Pharmacological Reviews
Elsevier Inc. | United States

Drug Resistance Updates
Churchill Livingstone | United Kingdom

Journal for ImmunoTherapy of Cancer
BMJ Publishing Group | United Kingdom

Annual Review of Pharmacology and Toxicology
Annual Reviews Inc. | United States

Molecular Therapy
Cell Press | United States

Pharmacology and Therapeutics
Elsevier Inc. | United States

Trends in Pharmacological Sciences
Elsevier Ltd | United Kingdom

Acta Pharmaceutica Sinica B
Chinese Academy of Medical Sciences | China

Theranostics
Ivyspring International Publisher | Australia

See All